Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.

Fabian Jost-BrinkmannMünevver DemirAlexander WreeTom LueddeSven H LoosenTobias Mueller Frank TackeChristoph RoderburgRaphael Mohr

Published in: Alimentary pharmacology & therapeutics (2023)

Atezolizumab plus bevacizumab showed good efficacy and safety in patients with unresectable HCC and partially advanced liver cirrhosis in a real-world setting. Moreover, the NLR was able to predict response to atezolizumab/bevacizumab treatment and may guide patient selection.

Keyphrases

metastatic colorectal cancer
locally advanced
liver metastases
case report
squamous cell carcinoma
radiation therapy
combination therapy
rectal cancer
replacement therapy